iCAD to Present at SunTrust Robinson Humphrey's 37th Annual Institutional UnConference

NASHUA, N.H., April 11 /PRNewswire-FirstCall/ -- iCAD, Inc. (Nasdaq: iCAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, today announced that Ken Ferry, President and Chief Executive Officer and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer, will be giving a corporate presentation at SunTrust Robinson Humphrey's 37th Annual Institutional UnConference on Wednesday, April 16, 2008 at 8:00 a.m. EDT at the Ritz Carlton, Buckhead in Atlanta, Georgia.

SunTrust Robinson Humphrey's 37th Annual Institutional UnConference connects company executives and management teams with investors, where investors will have the opportunity to personally meet with management teams in intimate one-on-one and small group meetings.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by more than 2,000 women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com.

For iCAD Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn &

Associates at 212-838-3777 x6604 or via email at [email protected]

For iCAD Public Relations, contact Jill Testagrossa of Schwartz Communications

SOURCE iCAD, Inc.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.